LOS ANGELES--(BUSINESS WIRE)--Cougar Biotechnology, Inc. (OTCBB: CGRB) today announced that positive interim Phase I and Phase II data on the Company’s prostate cancer drug candidate CB7630 (abiraterone acetate) was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, which is currently taking place in Chicago, Illinois. The data was presented in two poster presentations on Saturday, June 2nd, as part of the poster discussion session for genitourinary (prostate) cancer that took place. The poster presentations are further detailed below:
